Kymera added to Citi catalyst watch list on atopic dermatitis asset data readout

[Wall street.]
bodrumsurf

* Citi has added Kymera Therapeutics (NASDAQ:KYMR [https://seekingalpha.com/symbol/KYMR]) to its 90-day catalyst watch list ahead of a phase 1b data release expected in November for its oral STAT6 degrader KT-621 for atopic dermatitis.
* The bank rates the biotech a buy with an $80 price target (~39% upside based on Oct. 23 close).
* Analyst Geoff Meacham said that the phase 1b readout is poised for positive results given that phase 1a data showed profound STAT6 degradation of 90%-95% as well as a clean safety profile.
* But he added that given the phase 1b study is open-label and only enrolled about 20 participants, it "adds risk to interpreting the efficacy signal."
* Meacham noted that success for KT-621 will be based on the candidate's ability to meet the 4-week efficacy/biomarker profile of Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) and Regeneron Pharmaceuticals' (REGN [https://seekingalpha.com/symbol/REGN]) IL-4 receptor alpha antagonist Dupixent (dupilumab), which is given as a subcutaneous injection.

MORE ON KYMERA THERAPEUTICS

* Kymera Therapeutics, Inc. (KYMR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4821135-kymera-therapeutics-inc-kymr-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* Kymera Therapeutics, Inc. (KYMR) Presents At Citi's 2025 Biopharma Back To School Conference Transcript [https://seekingalpha.com/article/4819039-kymera-therapeutics-inc-kymr-presents-at-citis-biopharma-back-to-school-conference-transcript]
* Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4812261-kymera-therapeutics-inc-kymr-q2-2025-earnings-call-transcript]
* Kymera is a new Outperform at RBC Capital Markets on lead asset [https://seekingalpha.com/news/4495323-kymera-stock-is-new-outperform-rbc]
* Kymera extends cash runway to 2H 2028 as immunology pipeline advances and collaborations boost funding [https://seekingalpha.com/news/4483344-kymera-extends-cash-runway-to-2h-2028-as-immunology-pipeline-advances-and-collaborations]